Ingevity Corp (NGVT) · Nov 4, 2026 · Earnings
Beat — Diluted adjusted EPS $1.63 vs ~$1.56 consensus
Ingevity earnings modestly beat Q3 expectations and tightened 2026 EBITDA guidance, but weaker free cash flow and a delayed APT sale temper the read.
Ingevity is midway through a portfolio simplification: Performance Materials is the core earnings engine, while Pavement Technologies is under pressure and Advanced Polymer Technologies is being prepared for a potential sale. The company had been targeting a year-end 2026 strategic outcome for APT, making the timing update relevant even though the broader direction was already known.
The quarter modestly beat the operating bar. Diluted adjusted EPS was $1.63 versus a published consensus of roughly $1.56, while revenue of $305.1 million was slightly above the roughly $303.9 million expectation. The beat came with mixed underlying demand: Performance Materials held EBITDA essentially flat despite softer automotive volumes overseas, Advanced Polymer Technologies improved, but Pavement Technologies EBITDA fell sharply as demand and input costs weighed.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net sales (Financial Highlights) | $305.1M (+0.5%) | $333.1M | $303.9M |
| Diluted adjusted EPS (Adjusted EPS reconciliation) | $1.63 (+24.4%) | $1.31 | ~$1.56 |
| Adjusted EBITDA (Adjusted EBITDA reconciliation) | $108.0M (-2.2%) | $110.4M | |
| Free cash flow (Free Cash Flow Calculation) | $85.5M (-27.4%) | $117.8M |
The guidance change is better than a simple reaffirmation, but not a major reset. Full-year adjusted EBITDA is now narrowed to $385 million-$395 million from $380 million-$400 million, lifting the midpoint from $390 million to $390 million while reducing the range of outcomes. The adjusted EPS range also moves up at the low end to $5.25-$5.45 from $5.00-$5.45, implying better visibility rather than a higher top-end ambition. The company’s prior outlook had included the same broad EBITDA framework and full-year APT results.
The cash-flow picture is less clean. Third-quarter free cash flow fell to $85.5 million, and the new full-year range of $220 million-$230 million trims the prior $220 million-$245 million range, reflecting higher capital spending and working-capital investment. That matters because deleveraging and shareholder returns are central to the post-restructuring story, even though net leverage remained at 2.5x and below the prior-year 2.7x.
The APT strategic catalyst is pushed out, not removed. Management said an announced agreement may extend into early 2027 rather than arrive within 2026. That is a timing setback for the portfolio simplification plan, but it does not change the stated intention to pursue a sale; meanwhile, APT’s quarterly revenue rose 18% and EBITDA improved modestly, giving the business a better operating profile while it remains in the portfolio. 〔0〕
Bottom line: This is a modestly better quarter with tighter, slightly improved earnings visibility, but lower cash-flow guidance and a delayed APT sale keep it from being a clean upgrade to the story.
APT sale agreement, potentially early 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!